Locations:

Tag: immune checkpoint inhibitor

Immune checkpoint inhibitor illustration

April 8, 2025/Cancer

Building on Initial Trial Data about New Immune Checkpoint Inhibitor for Treating Colorectal Cancer

Insights indicate that treatment may be beneficial beyond MSI-H tumors

September 16, 2024/Cancer/Research

New Studies Reinforce Benefits of Combination Treatment for Urothelial Carcinoma

Enfortumab vedotin plus pembrolizumab benefited patients, regardless of biomarker expression

December 27, 2023/Cancer/Research

A New Standard Emerges in Advanced Urothelial Carcinoma After Decades of First-Line Chemotherapy

Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy

23-CNR-4162210-CQD-Hero-650×450 Dr Khorana

October 12, 2023/Cancer/Research

Study Delves into the Mechanisms Causing Venous Thromboembolism in Patients Receiving Immunotherapies

Clinicians highlight the need to educate patients about warning signs

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

March 3, 2020/Cancer/News & Insight

Case Report: Merkel Cell Carcinoma Patients Respond to Investigational Combination Therapy

Immune checkpoint inhibitor and oncolytic viral immunotherapy produce synergistic effect

August 20, 2019/Cancer

Immunotherapy for Non-Small Cell Lung Cancer Brain Metastases: Ready for Prime Time

Companion studies reveal efficacy indicators for PD-1/PD-L1 inhibition

BackPage 1 of 1Next